γδ-T cells: an unpolished sword in human anti-infection immunity

Abstract

cd-T cells represent a small population of immune cells, but play an indispensable role in host defenses against exogenous pathogens, immune surveillance of endogenous pathogenesis and even homeostasis of the immune system. Activation and expansion of cd-T cells are generally observed in diverse human infectious diseases and correlate with their progression and prognosis. cd-T cells have both 'innate' and 'adaptive' characteristics in the immune response, and their anti-infection activities are mediated by multiple pathways that are under elaborate regulation by other immune components. In this review, we summarize the current state of the literature and the recent advancements in cd-T cell-mediated immune responses against common human infectious pathogens. Although further investigation is needed to improve our understanding of the characteristics of different cd-T cell subpopulations under specific conditions, cd-T cell-based therapy has great potential for the treatment of infectious diseases.

The interaction of influenza H5N1 viral hemagglutinin with sialic acid receptors leads to the activation of human γδ T cells

“…[12][13][14] Recent studies demonstrated that cd T cells can kill both human and avian influenza virus-infected monocyte-derived macrophages. 15,16 cd T cells from human peripheral blood mononuclear cells (PBMCs) can be activated by influenza A infection.…”

Heterogeneous yet stable Vδ2 (+) T-cell profiles define distinct cytotoxic effector potentials in healthy human individuals

“…human γδ T cells | Vδ2 (+) T cells | antitumor cytotoxicity | functional heterogeneity | human immunology H uman γδ T cells display potent responses to pathogens and malignancies (1)(2)(3). Of particular interest are those that express TCRδ-chain variable-region-2 [Vδ2 (+) ] (4).…”

Osteonecrosis of the jaw associated with antiresorptives: more evidence on the role of infection

“…Recent publications provide new insights on its central role and possible mechanisms involved. gdT cells that have critical roles in the early response to invasive pathogens and also constitute the major subset of resident T cells in mucosa and skin 6 were reduced significantly in the peripheral blood of naive or previous users of oral or IV N-BPs and osteoporotic patients treated with zoledronate. 7 Kalyan et al 8 reported similar findings in patients treated with alendronate weekly (70 mg), 150 mg oral ibandronate monthly or 3 mg IV every 3 months and in cancer patients treated with zoledronate.…”